COVID Moonshot

Last updated
External videos
Nuvola apps kaboodle.svg "How Humans Are Crowdsourcing a Cure to COVID-19", Coffee Break, May 3, 2020
Nuvola apps kaboodle.svg “Data coordination strategies used in the COVID Moonshot initiative”, Lizbe Koekemoer, Oxford University, November 17, 2020
Nuvola apps kaboodle.svg "Could the COVID Moonshot change how we design drugs?", Folding@home, January 21, 2021

COVID Moonshot is a collaborative open-science project started in March 2020 with the goal of developing an un-patented oral antiviral drug to treat SARS-CoV-2, the virus causing COVID-19. [1] [2] COVID Moonshot researchers are targeting the proteins needed to form functioning new viral proteins. [3] They are particularly interested in proteases such as 3C-like protease (Mpro), a coronavirus nonstructural protein that mediates the breaking and replication of proteins. [2]

Contents

COVID Moonshot may be the first open-science community effort for the development of an antiviral drug. [2] Hundreds of scientists around the world, from academic and industrial organizations, have shared their expertise, resources, data, and results to more rapidly identify, screen, and test candidate compounds for the treatment of COVID-19. [4]

Project history

Development of antiviral drugs is a complicated and time-consuming multistage process. [5] The public sharing of information in the early stages of genome identification and protein structure identification has accelerated the process of searching for COVID-19 treatments and established a basis for the COVID Moonshot initiative. [6] [7]

Genome identification

On January 3, 2020, Chinese virologist Yong-Zhen Zhang of Fudan University and the Shanghai Public Health Clinical Center received a test sample from Wuhan, China, where patients had a pneumonia-like illness. By January 5, Zhang and his team had sequenced a virus from the sample and deposited its genome on GenBank, an international research database maintained by the United States National Center for Biotechnology Information. [8] [9] By January 11, 2020, Edward C. Holmes of the University of Sydney had Zhang's permission to publicly release the genome. [8] [10]

Protein structures

With that information, structural biologists world-wide began examining its protein structures. Investigators from the Center for Structural Genomics of Infectious Diseases (CSGID) and other groups began working to characterize the 3D structure of the proteins, sharing their results via the Protein Data Bank (PDB). [6] [7] [11]

SARS-CoV-2 main proteinase dimer with the catalytic dyad (H41; C145) in complex with protease inhibitor chemical 11a (PDB: 6LZE ) DOI.10.1126.science.abb4489.S2.png
SARS-CoV-2 main proteinase dimer with the catalytic dyad (H41; C145) in complex with protease inhibitor chemical 11a ( PDB: 6LZE ​)

Scientists were able to identify a key protein in the virus: 3C-like protease (Mpro). [6] [7] Crucial early X-ray crystallography was done by Zihe Rao and Haitao Yang in Shanghai, China. On January 26, 2020, they submitted a structure of Mpro bound to an inhibitor to the Protein Data Bank. It was released as of February 5, 2020. [6] [7] Rao began coordinating with David Stuart and Martin Walsh at Diamond Light Source, the United Kingdom's synchrotron facility. The Diamond group was able to develop and release a high-resolution crystal structure of unbound Mpro. [6] [7]

Approaches to accelerating drug development have been suggested, but identification of proteins and drug development commonly take years. [5] [6] It was possible to sequence the virus and characterize key proteins extremely quickly because the new virus was somewhat familiar. It had a 70–80% sequence similarity to the proteins in the SARS-CoV coronavirus that caused the SARS outbreak in 2002. Researchers could therefore build on what was already known about previous coronaviruses. [6]

Possible targets

Identifying and recreating viral proteins in the lab is a first step to developing drugs to attack them and vaccines to protect against them. [6] The COVID Moonshot initiative follows an approach to structure-based drug design in which researchers attempt to find a molecule that will bind tightly to a drug target and prevent it from carrying out its normal activities. [7] [2]

In the case of SARS-CoV-2, the coronavirus enters the body and then replicates its genomic RNA, building new copies that are incorporated into new, rapidly spreading viral particles. Protease enzymes or proteases are often desirable drug targets, because proteases are important in the formation and spreading of viral particles. Inhibition of viral proteases can inhibit the virus's ability to replicate itself and spread. [12]

3C-like protease (Mpro), a coronavirus nonstructural protein, is one of the main proteins involved in the replication and transcription of SARS-CoV-2. By understanding Mpro's structure and the ways in which it functions, scientists can identify possible candidates to preemptively bind to Mpro and block its activity. Mpro is not the only possible target for drug design, but it is a highly interesting one. [12]

Fragment screening

In collaboration with the University of Oxford and the Weizmann Institute of Science in Rehovot, Israel, the facilities at Diamond Light were used to develop fragment screens [13] [14] [15] [7] utilizing crystallography [16] and mass spectrometry. [17] [18] Nir London's laboratory at the Weizmann Institute contributed technology for identifying compounds that bind irreversibly to target proteins. [4] Frank von Delft and the Nuffield Department of Medicine at the University of Oxford provided technology for rapid crystallographic fragment screening. [4]

Researchers examined thousands of possible fragments from diverse screening libraries and identified at least 71 possible protein–ligand crystal structures, chemical fragments which might have the potential to bind to Mpro. [19] [15] These results were immediately made available online. [4] [15]

Designing candidates

The open release of the data and its announcement on Twitter on March 7, 2020, mark a critical point in the formation of COVID Moonshot. The scientists shared their information and challenged chemists worldwide to use that information to design potential openly available antiviral drug candidates. [7] [6] [9] They expected a couple of hundred submissions. By May 2020 more than 4,600 design submissions for potential inhibitors were received. [6] By January 2021, the number of unique compound designs had risen to 14,000. [7] In response, those involved began to shift from a spontaneous virtual collaboration to a larger and more organized network of partners with specialized skills and well-articulated goals. [20]

The original crowdsourced design of the fragment merge (TRY-UNI-714a760b-6) Figure 4 doi.org-10.1101-2020.10.29.339317.png
The original crowdsourced design of the fragment merge (TRY-UNI-714a760b-6)

The design submissions were stored in Collaborative Drug Discovery's CDD Vault, a database used for large-scale management of chemical structures, experimental protocols and experimental results. [4] Alpha Lee and Matt Robinson brought computational expertise from PostEra to the project. PostEra used techniques from artificial intelligence and machine learning to develop analysis tools for computational drug discovery, chemical synthesis and biochemical assays. When COVID Moonshot's appeal resulted in not hundreds but thousands of responses, they built a platform capable of triaging large numbers of compounds and designing routes for their synthetic formation. [4]

Supercomputer access was provided through the COVID-19 High Performance Computing (HPC) Consortium, accelerating the speed at which designs could be examined and compared. [21] [22] The distributed supercomputing initiative Folding@home has carried out multiple sprints to model novel protein structures and target desirable structures as a part of COVID Moonshot. [23] [24] [25]

Many of the criteria for selecting drug candidates were determined by the group's goals. An ideal drug candidate would be effective in treating COVID-19. It also would be easily and cheaply made, so that as many countries and companies as possible could produce and distribute it. The ingredients to make it should be easy to obtain, and the processes involved should be as simple as possible. A drug shouldn't require special handling (like refrigeration) and it should be easy to administer (a pill rather than an injection). [4] [20]

In a matter of months, researchers were able to identify more than 200 promising crystal structure designs and to begin creating and testing them in the lab. [26] [27] Chris Schofield at the University of Oxford synthesized and tested 4 of the most promising of the novel designed peptides to demonstrate their ability to block and inhibit Mpro. [27] Freely available data from COVID Moonshot has also been used to assess the predictive ability of docking scores in suggesting the potency of SARS-CoV-2 M-pro inhibitors. [28]

To go beyond the design phase, possible drug candidates must be created and tested for both effectiveness and safety in animal and human trials. [29] The Wellcome Trust has committed to key initial funding to support this process. [20] Synthesis of candidates is being carried out in parallel, at sites including Ukraine (Enamine), India (Sai Life Sciences) and China (WuXi). [25] Annette von Delft of the University of Oxford and the National Institute for Health Research (NIHR)'s Oxford Biomedical Research Centre (BRC) is leading pre-clinical small molecule research related to COVID Moonshot. [30]

Potential for antiviral treatments

COVID Moonshot anticipates that they will select three pre-clinical candidates by March 2022,[ needs update ] to be followed by preclinical safety and toxicology testing and identification of needed chemistry, manufacturing and control (CMC) steps. Based on that data, the most promising candidate will be chosen. Phase-1 clinical trials, the first stage of testing in human subjects, are projected to begin by June 2023. [31] [20]

Unlike a vaccine, which increases immunity and protects against catching an infectious disease, an antiviral drug treats someone who is already sick by attacking the virus and countering its effects, potentially lessening both symptoms and further transmission. [2]

Mpro is present in other coronaviruses that cause disease, so an antiviral drug that targets Mpro may also be effective against coronaviruses such as SARS and MERS and future pandemics.[ citation needed ]

Mpro does not mutate easily, so it is less likely that variants of the virus will adapt that can avoid the effects of such a drug. [2]

Open science

Some of the international participants in COVID Moonshot. Figure 1 doi.org-10.1101-2020.10.29.339317.png
Some of the international participants in COVID Moonshot.

Among the many participants in the COVID Moonshot project are the University of Oxford, University of Cambridge, Diamond Light Source, Weizmann Institute of Science in Rehovot, Israel, [32] [19] Temple University, [4] Memorial Sloan Kettering Cancer Center, PostEra, University of Johannesburg, and the Drugs for Neglected Diseases initiative (DNDi) in Switzerland. [20] Support for the project has come from a variety of philanthropic sources including the Wellcome Trust, COVID-19 Therapeutics Accelerator (CTA), Bill & Melinda Gates Foundation, [33] [20] LifeArc, [34] and through crowdsourcing. [4]

Because COVID Moonshot is based in open science and shared open data, any drug that the project develops can be manufactured and sold by whoever wishes to produce it, worldwide. Countries that are unable to buy or manufacture expensive licensed drugs would therefore have the opportunity to produce their own supplies, and competition between suppliers is likely to result in greater availability and reduced prices for consumers. [4]

This would circumvent issues around the time needed to vaccinate people worldwide. As of July 2021, it was estimated that at current rates, this was likely to take several years. Inequities in distribution will increase both the spreading of the virus and the risk that new and more dangerous variants will emerge. [35] [36]

Supporters of the COVID Moonshot initiative have argued that open-science drug discovery is an essential model for combating both current and future pandemics, and that the prevention of the spread of pandemic diseases is an essential public service. [4]

Related Research Articles

<span class="mw-page-title-main">SARS-related coronavirus</span> Species of coronavirus causing SARS and COVID-19

Severe acute respiratory syndrome–related coronavirus is a species of virus consisting of many known strains phylogenetically related to severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) that have been shown to possess the capability to infect humans, bats, and certain other mammals. These enveloped, positive-sense single-stranded RNA viruses enter host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. The SARSr-CoV species is a member of the genus Betacoronavirus and of the subgenus Sarbecovirus.

Protease inhibitors (PIs) are medications that act by interfering with enzymes that cleave proteins. Some of the most well known are antiviral drugs widely used to treat HIV/AIDS, hepatitis C and COVID-19. These protease inhibitors prevent viral replication by selectively binding to viral proteases and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles.

<span class="mw-page-title-main">Ritonavir</span> Antiretroviral medication

Ritonavir, sold under the brand name Norvir, is an antiretroviral medication used along with other medications to treat HIV/AIDS. This combination treatment is known as highly active antiretroviral therapy (HAART). Ritonavir is a protease inhibitor and is used with other protease inhibitors. It may also be used in combination with other medications to treat hepatitis C and COVID-19. It is taken by mouth. Tablets of ritonavir are not bioequivalent to capsules, as the tablets may result in higher peak plasma concentrations.

<span class="mw-page-title-main">TMPRSS2</span> Protein-coding gene in the species Homo sapiens

Transmembrane protease, serine 2 is an enzyme that in humans is encoded by the TMPRSS2 gene. It belongs to the TMPRSS family of proteins, whose members are transmembrane proteins which have a serine protease activity. The TMPRSS2 protein is found in high concentration in the cell membranes of epithelial cells of the lung and of the prostate, but also in the heart, liver and gastrointestinal tract.

<span class="mw-page-title-main">Camostat</span> Serine protease inhibitor

Camostat is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range of uses. Camostat is approved in Japan for the treatment of chronic pancreatitis and postoperative reflux esophagitis. The oral proteolytic enzyme inhibitor has been on the market since 1985 under the trade name Foipan Tablets. The manufacturer is Ono Pharmaceutical. The drug is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis.

<span class="mw-page-title-main">Simeprevir</span> Chemical compound

Simeprevir, sold under the brand name Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C. It is specifically used for hepatitis C genotype 1 and 4. Medications it is used with include sofosbuvir or ribavirin and peginterferon-alfa. Cure rates are in 80s to 90s percent. It may be used in those who also have HIV/AIDS. It is taken by mouth once daily for typically 12 weeks.

<span class="mw-page-title-main">3C-like protease</span> Class of enzymes

The 3C-like protease (3CLpro) or main protease (Mpro), formally known as C30 endopeptidase or 3-chymotrypsin-like protease, is the main protease found in coronaviruses. It cleaves the coronavirus polyprotein at eleven conserved sites. It is a cysteine protease and a member of the PA clan of proteases. It has a cysteine-histidine catalytic dyad at its active site and cleaves a Gln–(Ser/Ala/Gly) peptide bond.

<span class="mw-page-title-main">SARS-CoV-2</span> Virus that causes COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a strain of coronavirus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic. The virus previously had the provisional name 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019. First identified in the city of Wuhan, Hubei, China, the World Health Organization designated the outbreak a public health emergency of international concern from January 30, 2020, to May 5, 2023. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans.

<span class="mw-page-title-main">COVID-19 drug repurposing research</span> Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

<span class="mw-page-title-main">COVID-19 drug development</span> Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

<span class="mw-page-title-main">3CLpro-1</span> Chemical compound

3CLpro-1 is an antiviral drug related to rupintrivir which acts as a 3CL protease inhibitor and was originally developed for the treatment of human enterovirus 71. It is one of the most potent of a large series of compounds developed as inhibitors of the viral enzyme 3CL protease, with an in vitroIC50 of 200 nM. It also shows activity against coronavirus diseases such as SARS and MERS, and is under investigation as a potential treatment agent for the viral disease COVID-19.

<span class="mw-page-title-main">GC376</span> Broad-spectrum antiviral medication

GC376 is a broad-spectrum antiviral medication under development by the biopharmaceutical company Anivive Lifesciences for therapeutic uses in humans and animals. Anivive licensed the exclusive worldwide patent rights to GC376 from Kansas State University. As of 2020, GC376 is being investigated as treatment for COVID-19. GC376 shows activity against many human and animal viruses including coronavirus and norovirus; the most extensive research has been multiple in vivo studies in cats treating a coronavirus which causes deadly feline infectious peritonitis. Other research supports use in porcine epidemic diarrhea virus.

Broad-spectrum antivirals (BSAs) are a class of molecules or compounds, which inhibit the infection of multiple viruses from the same or different virus families. BSAs could be divided into experimental and investigational agents, and approved drugs. BSAs work by inhibiting viral proteins or by targeting host cell factors and processes exploited by different viruses during infection. As of 2021, there are 150 known BSAs in varying stages of development, effective against 78 human viruses. BSAs are potential candidates for treatment of emerging and re-emerging viruses, such as ebola, marburg, and SARS-CoV-2. Many BSAs show antiviral activity against other viruses than originally investigated. Efforts in drug repurposing for SARS-CoV-2 is currently underway. A database of BSAs and viruses they inhibit could be found here.

M. Joanne Lemieux is a Canadian scientist who is a Professor of Structural Biology at the University of Alberta. She studies the structures of membrane proteins that are critical to disease in an effort to identify novel therapeutic strategies. During the COVID-19 pandemic Lemieux worked to develop an antiviral drug that could protect people from coronavirus disease.

Jason S. McLellan is a structural biologist, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at The University of Texas at Austin who specializes in understanding the structure and function of viral proteins, including those of coronaviruses. His research focuses on applying structural information to the rational design of vaccines and other therapies for viruses, including SARS-CoV-2, the novel coronavirus that causes COVID-19, and respiratory syncytial virus (RSV). McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center to design a stabilized version of the SARS-CoV-2 spike protein, which biotechnology company Moderna used as the basis for the vaccine mRNA-1273, the first COVID-19 vaccine candidate to enter phase I clinical trials in the U.S. At least three other vaccines use this modified spike protein: those from Pfizer and BioNTech; Johnson & Johnson and Janssen Pharmaceuticals; and Novavax.

<span class="mw-page-title-main">Nirmatrelvir</span> COVID-19 antiviral medication

Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir combination used to treat COVID-19 and sold under the brand name Paxlovid.

<span class="mw-page-title-main">Lufotrelvir</span> Chemical compound

Lufotrelvir (PF-07304814) is an antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor. It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231. Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.

<span class="mw-page-title-main">Nidoviral papain-like protease</span> Papain-like protease protein domain

The nidoviral papain-like protease is a papain-like protease protein domain encoded in the genomes of nidoviruses. It is expressed as part of a large polyprotein from the ORF1a gene and has cysteine protease enzymatic activity responsible for proteolytic cleavage of some of the N-terminal viral nonstructural proteins within the polyprotein. A second protease also encoded by ORF1a, called the 3C-like protease or main protease, is responsible for the majority of further cleavages. Coronaviruses have one or two papain-like protease domains; in SARS-CoV and SARS-CoV-2, one PLPro domain is located in coronavirus nonstructural protein 3 (nsp3). Arteriviruses have two to three PLP domains. In addition to their protease activity, PLP domains function as deubiquitinating enzymes (DUBs) that can cleave the isopeptide bond found in ubiquitin chains. They are also "deISGylating" enzymes that remove the ubiquitin-like domain interferon-stimulated gene 15 (ISG15) from cellular proteins. These activities are likely responsible for antagonizing the activity of the host innate immune system. Because they are essential for viral replication, papain-like protease domains are considered drug targets for the development of antiviral drugs against human pathogens such as MERS-CoV, SARS-CoV, and SARS-CoV-2.

<span class="mw-page-title-main">Nirmatrelvir/ritonavir</span> Antiviral combination medication

Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged medication used as a treatment for COVID‑19. It contains the antiviral medications nirmatrelvir and ritonavir and was developed by Pfizer. Both are protease inhibitors: nirmatrelvir inhibits SARS-CoV-2 main protease, while ritonavir inhibits HIV-1 protease, and is additionally a strong CYP3A inhibitor.

<span class="mw-page-title-main">Ensitrelvir</span> COVID-19 SARS-CoV-2 3CL-protease-inhibitor antiviral drug

Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth.

References

  1. ↑ Whipple, Tom (October 23, 2021). "Moonshot is the spanner in the Covid-19 works the country needs". The Times. Retrieved 5 November 2021.
  2. 1 2 3 4 5 6 Lee, Alpha; Chodera, John; von Delft, Frank (27 September 2021). "Why we are developing a patent-free Covid antiviral therapy". Knowable Magazine. doi:10.1146/knowable-092721-1. S2CID   244170138 . Retrieved 1 November 2021.
  3. ↑ Dance, Amber (9 February 2021). "The challenges of antiviral treatments". Knowable Magazine. doi:10.1146/knowable-020821-2. S2CID   233922849 . Retrieved 1 November 2021.
  4. 1 2 3 4 5 6 7 8 9 10 11 Thomas, Uduak Grace (12 August 2020). "The COVID-19 antiviral race: we're all in this together". Drug Discovery World. Vol. 21, no. 3. Retrieved 1 November 2021.
  5. 1 2 Everts, Maaike; Cihlar, Tomas; Bostwick, J. Robert; Whitley, Richard J. (6 January 2017). "Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model". Annual Review of Pharmacology and Toxicology. 57 (1): 155–169. doi:10.1146/annurev-pharmtox-010716-104533. ISSN   0362-1642. PMID   27483339 . Retrieved 2 November 2021.
  6. 1 2 3 4 5 6 7 8 9 10 Scudellari, Megan (19 May 2020). "The sprint to solve coronavirus protein structures — and disarm them with drugs". Nature. Retrieved 2 November 2021.
  7. 1 2 3 4 5 6 7 8 9 Walsh, Martin A.; Grimes, Jonathan M.; Stuart, David I. (January 2021). "Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics". Biochemical and Biophysical Research Communications. 538: 40–46. doi:10.1016/j.bbrc.2020.11.041. PMC   7676326 . PMID   33248689.
  8. 1 2 Cyranoski, David (14 December 2020). "Nature's 10: ten people who helped shape science in 2020 : Zhang Yongzhen: Genome sharer". Nature. Retrieved 2 November 2021.
  9. 1 2 Howes, Laura (May 2, 2020). "How structural biologists revealed the new coronavirus's structure so quickly". Chemical & Engineering News. 98 (17). Retrieved 5 November 2021.
  10. ↑ Holmes, Edward (11 January 2020). "Novel 2019 coronavirus genome". virological.org. Retrieved 2 November 2021.
  11. ↑ "Structural Genomics Centers for Infectious Diseases". National Institute of Allergy and Infectious Diseases (NIAID). 7 May 2021. Retrieved 2 November 2021.
  12. 1 2 Mengist, Hylemariam Mihiretie; Dilnessa, Tebelay; Jin, Tengchuan (2021). "Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease". Frontiers in Chemistry. 9: 7. doi: 10.3389/fchem.2021.622898 . ISSN   2296-2646. PMC   8056153 . PMID   33889562.
  13. ↑ Ahuja, Anjana (7 April 2020). "How to marshal a crowd to launch a moonshot against Covid-19". Financial Times. Retrieved 5 November 2021.
  14. ↑ Mazzorana, Marco; Shotton, Elizabeth J.; Hall, David R. (10 December 2020). "A comprehensive approach to X-ray crystallography for drug discovery at a synchrotron facility — The example of Diamond Light Source". Drug Discovery Today: Technologies. 37: 83–92. doi: 10.1016/j.ddtec.2020.10.003 . ISSN   1740-6749. PMID   34895658. S2CID   230551125.
  15. 1 2 3 Douangamath, Alice; Fearon, Daren; Gehrtz, Paul; Krojer, Tobias; Lukacik, Petra; Owen, C. David; Resnick, Efrat; Strain-Damerell, Claire; Aimon, Anthony; Ábrányi-Balogh, Péter; Brandão-Neto, José; Carbery, Anna; Davison, Gemma; Dias, Alexandre; Downes, Thomas D.; Dunnett, Louise; Fairhead, Michael; Firth, James D.; Jones, S. Paul; Keeley, Aaron; Keserü, György M.; Klein, Hanna F.; Martin, Mathew P.; Noble, Martin E. M.; O’Brien, Peter; Powell, Ailsa; Reddi, Rambabu N.; Skyner, Rachael; Snee, Matthew; Waring, Michael J.; Wild, Conor; London, Nir; von Delft, Frank; Walsh, Martin A. (7 October 2020). "Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease". Nature Communications. 11 (1): 5047. Bibcode:2020NatCo..11.5047D. doi:10.1038/s41467-020-18709-w. ISSN   2041-1723. PMC   7542442 . PMID   33028810 . Retrieved 3 November 2021.
  16. ↑ Badger, John (2012). "Crystallographic Fragment Screening". Structure-Based Drug Discovery. Methods in Molecular Biology. Vol. 841. Humana Press. pp. 161–177. doi:10.1007/978-1-61779-520-6_7. ISBN   978-1-61779-519-0. PMID   22222452 . Retrieved 3 November 2021.
  17. ↑ Chan, Daniel Shiu-Hin; Whitehouse, Andrew J.; Coyne, Anthony G.; Abell, Chris (8 November 2017). "Mass spectrometry for fragment screening". Essays in Biochemistry. 61 (5): 465–473. doi:10.1042/EBC20170071. ISSN   0071-1365. PMID   28986384 . Retrieved 3 November 2021.
  18. ↑ Kantsadi, Anastassia L.; Cattermole, Emma; Matsoukas, Minos-Timotheos; Spyroulias, Georgios A.; Vakonakis, Ioannis (2021). "A COVID moonshot: assessment of ligand binding to the SARS-CoV-2 main protease by saturation transfer difference NMR spectroscopy". Journal of Biomolecular NMR. 75 (4): 167–178. doi:10.1007/s10858-021-00365-x. ISSN   0925-2738. PMC   8047523 . PMID   33856612.
  19. 1 2 Chodera, John; Lee, Alpha A.; London, Nir; von Delft, Frank (July 2020). "Crowdsourcing drug discovery for pandemics". Nature Chemistry. 12 (7): 581. Bibcode:2020NatCh..12..581C. doi: 10.1038/s41557-020-0496-2 . ISSN   1755-4349. PMID   32555379. S2CID   219906197.
  20. 1 2 3 4 5 6 "COVID Moonshot funded by COVID-19 Therapeutics Accelerator to rapidly develop a safe, globally accessible and affordable antiviral pill". Drugs for Neglected Diseases Initiative (DNDi). 27 September 2021. Retrieved 3 November 2021.
  21. ↑ Wiggers, Kyle (28 May 2020). "COVID-19 HPC Consortium pours 437 petaflops of compute power toward virus research". VentureBeat. Retrieved 5 November 2021.
  22. ↑ Morris, Aaron. "PostEra: COVID MoonShot". COVID-19 HPC Consortium. Retrieved 5 November 2021.
  23. ↑ Masterson, Victoria (22 December 2020). "Your computer can help scientists find a cure for COVID-19. Here's how". World Economic Forum. Retrieved 5 November 2021.
  24. ↑ "Together We Are Powerful". FOLDINGATHOME. Retrieved 5 November 2021.
  25. 1 2 von Delft, Frank; Calmiano, Mark; Chodera, John; Griffen, Ed; Lee, Alpha; London, Nir; Matviuk, Tatiana; Perry, Ben; Robinson, Matt; von Delft, Annette (June 2021). "A white-knuckle ride of open COVID drug discovery". Nature. 594 (7863): 330–332. Bibcode:2021Natur.594..330V. doi: 10.1038/d41586-021-01571-1 . PMID   34127864. S2CID   235438395.
  26. ↑ Achdout, Hagit; et al. (30 October 2020). "Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics". BiorXiv. doi:10.1101/2020.10.29.339317. S2CID   239037333 . Retrieved 5 November 2021. ChemRxiv version
  27. 1 2 Chan, H. T. Henry; Moesser, Marc A.; Walters, Rebecca K.; Malla, Tika R.; Twidale, Rebecca M.; John, Tobias; Deeks, Helen M.; Johnston-Wood, Tristan; Mikhailov, Victor; Sessions, Richard B.; Dawson, William; Salah, Eidarus; Lukacik, Petra; Strain-Damerell, Claire; Owen, C. David; Nakajima, Takahito; Świderek, Katarzyna; Lodola, Alessio; Moliner, Vicent; Glowacki, David R.; Spencer, James; Walsh, Martin A.; Schofield, Christopher J.; Genovese, Luigi; Shoemark, Deborah K.; Mulholland, Adrian J.; Duarte, Fernanda; Morris, Garrett M. (2021). "Discovery of SARS-CoV-2 M pro peptide inhibitors from modelling substrate and ligand binding". Chemical Science. 12 (41): 13686–13703. doi:10.1039/D1SC03628A. PMC   8549791 . PMID   34760153.
  28. ↑ Macip, Guillem; Garcia-Segura, Pol; Mestres-Truyol, Júlia; Saldivar-Espinoza, Bryan; Ojeda-Montes, María José; Gimeno, Aleix; Cereto-Massagué, Adrià; Garcia-Vallvé, Santiago; Pujadas, Gerard (26 October 2021). "Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition". Medicinal Research Reviews. 42 (2): 744–769. doi:10.1002/med.21862. ISSN   1098-1128. PMC   8662214 . PMID   34697818. S2CID   239888873 . Retrieved 5 November 2021.
  29. ↑ Scudellari, Megan (4 December 2020). "COVID Moonshot Effort Generates "Elite" Antivirals". IEEE Spectrum. Retrieved 5 November 2021.
  30. ↑ "Moonshot initiative to develop affordable COVID-19 antivirals gets funding boost". University of Oxford. 28 September 2021. Retrieved 5 November 2021.
  31. ↑ von Delft, Annette; Mowbray, Charles; Nyaoke, Borna (24 December 2021). "The Moonshot: Crowdsourcing To Develop The First Open-Source, Generic COVID-19 Antiviral Pill - Health Policy Watch". Health Policy Watch. Retrieved 17 January 2022.
  32. ↑ "Israeli scientists to participate in int'l drive to find COVID-curing pills". The Jerusalem Post. September 29, 2021. Retrieved 5 November 2021.
  33. ↑ "COVID Moonshot consortium receives funding from Wellcome". Diamond Light. 2020. Retrieved 5 November 2021.
  34. ↑ "PostEra and LifeArc collaborate on novel open science initiative to develop new antiviral for COVID-19". LifeArc. 20 May 2021. Retrieved 5 November 2021.
  35. ↑ Safi, Michael (27 January 2021). "Most poor nations 'will take until 2024 to achieve mass Covid-19 immunisation'". The Guardian. Retrieved 5 November 2021.
  36. ↑ Padma, T. V. (5 July 2021). "COVID vaccines to reach poorest countries in 2023 — despite recent pledges". Nature. 595 (7867): 342–343. Bibcode:2021Natur.595..342P. doi: 10.1038/d41586-021-01762-w . PMID   34226742. S2CID   235744340.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.